ADVANZ PHARMA And Enzene Enter An Exclusive Partnership For Biosimilar Development And Commercialisation

ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia and Enzene Biosciences, a biopharmaceutical company specialising in the development and manufacturing of biosimilars, today announced a strategic partnership for the commercialisation of a proposed biosimilar for a rare disease indication. This partnership marks another important milestone in ADVANZ PHARMA’s commitment to expand access to high-quality biosimilar medicines.

Enzene’s biologic development and manufacturing expertise will be complemented by ADVANZ PHARMA’s market access and commercialisation capabilities in Europe.

Susanna El-Armale, Chief Corporate Development Officer at ADVANZ PHARMA, said: “This partnership underscores our commitment to bring impactful therapies to market. By leveraging Enzene’s development capabilities, we aim to improve access to a valuable treatment option, reinforcing our position as a partner of choice for commercialisation of specialty and rare disease medicines in Europe.”

Himanshu Gadgil, CEO of Enzene Biosciences, remarked, “Through strategic investments in advanced development and manufacturing capabilities, we have successfully lowered the cost of producing biosimilars, advancing our goal of delivering affordable healthcare to those with debilitating illnesses. Our partnership with Advanz Pharma aligns perfectly with this goal. Their extensive expertise in market access and commercialization, combined with a commitment to addressing unmet needs in rare disease treatments, positions us to significantly enhance the availability of affordable, life-saving therapies across Europe and beyond.”